Also known as Swedish Orphan Biovitrum.
None yet. When a new project in the record names Sobi as owner, partner or investor, it shows here.
First complement inhibitor in Japan for patients aged 12+ with these rare kidney diseases; VALIANT showed 68.1% proteinuria reduction and eGFR stabilization versus placebo.
